Base de dados : MEDLINE
Pesquisa : D10.251.355.255.550.775.450.750 [Categoria DeCS]
Referências encontradas : 93 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 10 ir para página                        

  1 / 93 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:9872499
[Au] Autor:Morris GP; Fallone CA; Pringle GC; MacNaughton WK
[Ad] Endereço:Department of Biology, Queen's University, Kingston, Ontario, Canada.
[Ti] Título:Gastric cytoprotection is secondary to increased mucosal fluid secretion: a study of six cytoprotective agents in the rat.
[So] Source:J Clin Gastroenterol;27 Suppl 1:S53-63, 1998.
[Is] ISSN:0192-0790
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:We tested the hypothesis that rapidly developing gastric cytoprotection produced by topical application of exogenous compounds is a result of increased gastric mucosal fluid secretion. Ex vivo gastric chambers were prepared in rats which were subsequently exposed topically to one of the prostaglandin (PG) E1 analogues misoprostol or rioprostil, PGE2, nicotine, N-ethylmaleimide (NEM), 0.25 M HCl, or to their respective vehicles. All agents were added to empty chambers to avoid complications resulting from dilution by gastric contents. Effects of these agents on intraluminal volume changes, blood flow, juxtamucosal pH, histology, and on the mucosal damage resulting from necrotizing agents were studied. All six agents were cytoprotective and each increased net secretion of fluid by the chambered mucosae. Gastric blood flow was not significantly increased by NEM, by 0.25 M HCl, or by nicotine compared to controls, and the juxtamucosal pH was not significantly increased by any of the three agents for which this was studied. Vacuole formation in surface epithelial cells and subepithelial edema were seen after exposure to some agents, but none of the agents led to formation of a thick barrier of exfoliated cells and mucus. Ablation of primary afferent nerves with capsaicin abolished both protection by 0.25 M HCl and the net increase in fluid secretion by the mucosae. Capsaicin ablation did not alter either the protection afforded by NEM or the increase in volume of secretion. We conclude that increased mucosal fluid secretion is the common factor present with all six cytoprotective agents and hence may be the predominant mechanism of cytoprotection against topically applied necrotizing agents.
[Mh] Termos MeSH primário: Antiulcerosos/farmacologia
Citoproteção
Dinoprostona/farmacologia
Etilmaleimida/farmacologia
Mucosa Gástrica/efeitos dos fármacos
Ácido Clorídrico/farmacologia
Nicotina/farmacologia
[Mh] Termos MeSH secundário: Animais
Capsaicina
Citotoxinas
Feminino
Mucosa Gástrica/irrigação sanguínea
Mucosa Gástrica/patologia
Mucosa Gástrica/secreção
Masculino
Misoprostol/farmacologia
Ratos
Ratos Sprague-Dawley
Fluxo Sanguíneo Regional/efeitos dos fármacos
Rioprostila/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Anti-Ulcer Agents); 0 (Cytotoxins); 0E43V0BB57 (Misoprostol); 6M3C89ZY6R (Nicotine); 7JL402PVQR (Rioprostil); K7Q1JQR04M (Dinoprostone); O3C74ACM9V (Ethylmaleimide); QTT17582CB (Hydrochloric Acid); S07O44R1ZM (Capsaicin)
[Em] Mês de entrada:9903
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:990101
[St] Status:MEDLINE


  2 / 93 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:8545392
[Au] Autor:Thijssen HW
[Ti] Título:[Interaction between prostaglandin E and oral anticoagulants].
[Ti] Título:Interaction de la prostaglandine E sur les anticoagulants oraux..
[So] Source:Presse Med;24(35):1665, 1995 Nov 18.
[Is] ISSN:0755-4982
[Cp] País de publicação:France
[La] Idioma:fre
[Mh] Termos MeSH primário: Antiulcerosos/metabolismo
Anticoagulantes/metabolismo
Rioprostila/metabolismo
[Mh] Termos MeSH secundário: Acenocumarol/administração & dosagem
Acenocumarol/metabolismo
Administração Oral
Anticoagulantes/administração & dosagem
Interações Medicamentosas
Seres Humanos
Femprocumona/administração & dosagem
Femprocumona/metabolismo
[Pt] Tipo de publicação:LETTER
[Nm] Nome de substância:
0 (Anti-Ulcer Agents); 0 (Anticoagulants); 7JL402PVQR (Rioprostil); I6WP63U32H (Acenocoumarol); Q08SIO485D (Phenprocoumon)
[Em] Mês de entrada:9602
[Cu] Atualização por classe:161209
[Lr] Data última revisão:
161209
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:951118
[St] Status:MEDLINE


  3 / 93 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:1941733
[Au] Autor:Purushotham AD; Gray GR; Hansell DT
[Ad] Endereço:Department of Surgery, Victoria Infirmary, Glasgow, UK.
[Ti] Título:Prostaglandins in the treatment of reflux oesophagitis: double-blind placebo controlled clinical trial.
[So] Source:J R Coll Surg Edinb;36(4):216-8, 1991 Aug.
[Is] ISSN:0035-8835
[Cp] País de publicação:Scotland
[La] Idioma:eng
[Ab] Resumo:The efficacy of the prostaglandin analogue, rioprostil, in the treatment of reflux oesophagitis has been assessed in a double-blind, randomized, placebo-controlled trial of 25 patients with endoscopic and histological evidence of reflux oesophagitis. At the beginning and end of the study, endoscopic appearances were graded 0-4 (0 = no oesophagitis, 4 = severe oesophagitis) and the symptoms of heartburn, regurgitation, pain and dysphagia were each graded 0-3 (0 = none, 3 = severe). Fourteen patients received rioprostil, 300 micrograms twice daily, and 11 patients received identically marked placebo for a period of 12 weeks. At the end of the study there were no significant differences between the groups in mean (s.d.) endoscopic grading (rioprostil 2.4 (1.3); placebo 1.9 (0.9)) and mean (s.d.) cumulative symptom score (rioprostil 2.5 (3.1); placebo 2.6 (1.5)). Five patients in the rioprostil group reported diarrhoea. Rioprostil had no significant benefit over placebo in the treatment of reflux oesophagitis.
[Mh] Termos MeSH primário: Esofagite Péptica/tratamento farmacológico
Rioprostila/uso terapêutico
[Mh] Termos MeSH secundário: Método Duplo-Cego
Feminino
Seres Humanos
Masculino
Meia-Idade
Rioprostila/efeitos adversos
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
7JL402PVQR (Rioprostil)
[Em] Mês de entrada:9112
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:910801
[St] Status:MEDLINE


  4 / 93 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:1908386
[Au] Autor:Grassi A; Ippen J; Bruno M; Thomas G
[Ad] Endereço:Department of Pharmacology, Bayer Italia, Garbagnate M.se MI.
[Ti] Título:BAY P 1455, a thiazolylaminobenzimidazole derivative with gastroprotective properties in the rat.
[So] Source:Eur J Pharmacol;195(2):251-9, 1991 Mar 26.
[Is] ISSN:0014-2999
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:The antiulcer activity of BAY P 14551 a thiazolylaminobenzimidazole derivative, was evaluated in different experimental ulcer models and its antiulcer activity was compared to that of different reference drugs. The overall activity of the compound was equal to or more potent than that of reference antiulcer drugs, such as pirenzepine, cimetidine and carbenoxolone, but it was not as potent as rioprostil. The ED50 values (expressed as mumol/kg p.o.) were 68 (confidence limits: 51-91) for indomethacin-induced ulcers, 21 (confidence limits: 13-31) for stress-induced ulcers and 1260 mumol/kg p.o. (confidence limits: 412-3800) for ulcers induced by absolute ethanol. The compound had no activity against cysteamine-induced duodenal ulcers and lost its cytoprotective activity in adrenalectomised rats. Since inhibition of gastric acid secretion was seen, if at all, only with the higher doses, the gastro-protective action of BAY P 1455 seemed not to be due to an antisecretory effect, but more likely to a gastroprotective action as hypothesised for prostaglandins.
[Mh] Termos MeSH primário: Antiulcerosos
Benzimidazóis/farmacologia
Tiazóis/farmacologia
[Mh] Termos MeSH secundário: Adrenalectomia
Animais
Cimetidina/farmacologia
Corticosterona/sangue
Cisteamina
Úlcera Duodenal/induzido quimicamente
Úlcera Duodenal/prevenção & controle
Etanol
Feminino
Ácido Gástrico/secreção
Imersão
Técnicas In Vitro
Indometacina
Masculino
Pirenzepina/farmacologia
Prostaglandinas E/farmacologia
Piloro/cirurgia
Ratos
Ratos Endogâmicos
Rioprostila
Úlcera Gástrica/etiologia
Úlcera Gástrica/prevenção & controle
Estresse Psicológico/complicações
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Ulcer Agents); 0 (Benzimidazoles); 0 (Prostaglandins E); 0 (Thiazoles); 131185-01-8 (2-(2'-benzimidazolyl)amino-4-methylthiazole); 3G0285N20N (Pirenzepine); 3K9958V90M (Ethanol); 5UX2SD1KE2 (Cysteamine); 7JL402PVQR (Rioprostil); 80061L1WGD (Cimetidine); W980KJ009P (Corticosterone); XXE1CET956 (Indomethacin)
[Em] Mês de entrada:9109
[Cu] Atualização por classe:141120
[Lr] Data última revisão:
141120
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:910326
[St] Status:MEDLINE


  5 / 93 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:1725159
[Au] Autor:Müller MK; Wojzek M; Rünzi M; von Schönfeld J; Goebell H; Singer MV
[Ad] Endereço:Medizinische Klinik IV, Universität Heidelberg, BRD.
[Ti] Título:Cytoprotective and dose-dependent inhibitory effects of prostaglandin E1 on rat pancreas treated with ciclosporin A.
[So] Source:Digestion;50(2):112-9, 1991.
[Is] ISSN:0012-2823
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:The prostaglandin E1 analogue rioprostil protects the pancreas from the noxious effect of ciclosporin A (CsA). To determine whether this cytoprotective action of rioprostil is dependent on or independent of inhibitory effects on pancreatic exocrine and endocrine secretion we studied the effect of different doses of rioprostil on pancreatic exocrine and endocrine secretions in the presence or absence of CsA. Rats received either CsA at a dose of 10 mg/kg body weight by tube feeding once in the morning, rioprostil at linearly increasing doses from 1.8 to 120 micrograms/kg body weight subcutaneously twice daily, a combination of both substances or NaCl. After 8 treatment days, the animals were operated on, and the pancreas isolated and arterially perfused. Insulin secretion was determined after stimulation with glucose, and amylase secretion after stimulation with CCK-8. Insulin and amylase secretion were significantly impaired by CsA. Rioprostil at doses of 1.8, 3.6 and 7.5 micrograms/kg body weight had no significant effect on insulin secretion in the absence of CsA but significantly improved insulin secretion in the presence of CsA. Higher doses of rioprostil significantly inhibited insulin secretion both in the presence or absence of CsA. Amylase secretion was not influenced by rioprostil at doses up to 15 micrograms/kg body weight but improved significantly amylase secretion in the presence of CsA. CsA blood and pancreatic tissue levels were not influenced by rioprostil at doses up to 120 micrograms/kb body weight. We conclude that the cytoprotective effect of the prostaglandin E1 analogue rioprostil against the noxious effect of CsA is dose dependent and is not related to its inhibitory action on endocrine and exocrine pancreatic secretion.
[Mh] Termos MeSH primário: Ciclosporina/efeitos adversos
Ilhotas Pancreáticas/efeitos dos fármacos
Pâncreas/efeitos dos fármacos
Rioprostila/uso terapêutico
[Mh] Termos MeSH secundário: Amilases/secreção
Animais
Ciclosporina/antagonistas & inibidores
Relação Dose-Resposta a Droga
Insulina/secreção
Masculino
Ratos
Ratos Endogâmicos
Rioprostila/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Insulin); 7JL402PVQR (Rioprostil); 83HN0GTJ6D (Cyclosporine); EC 3.2.1.- (Amylases)
[Em] Mês de entrada:9205
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:910101
[St] Status:MEDLINE


  6 / 93 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:1721286
[Au] Autor:Müller MK; Wojcik M; Coone H; Philipp T; Singer MV
[Ad] Endereço:Department of Medicine, Medical Clinic IV Mannheim, University of Heidelberg, Germany.
[Ti] Título:Inhibition of insulin release by FK 506 and its prevention by rioprostil, a stable prostaglandin E1 analogue.
[So] Source:Transplant Proc;23(6):2812-3, 1991 Dec.
[Is] ISSN:0041-1345
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Insulina/secreção
Ilhotas Pancreáticas/secreção
Rioprostila/farmacologia
Tacrolimo/farmacologia
[Mh] Termos MeSH secundário: Administração Oral
Animais
Glucose/farmacologia
Técnicas In Vitro
Injeções Subcutâneas
Ilhotas Pancreáticas/efeitos dos fármacos
Masculino
Perfusão
Ratos
Ratos Endogâmicos
Rioprostila/administração & dosagem
Tacrolimo/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Insulin); 7JL402PVQR (Rioprostil); IY9XDZ35W2 (Glucose); WM0HAQ4WNM (Tacrolimus)
[Em] Mês de entrada:9201
[Cu] Atualização por classe:141120
[Lr] Data última revisão:
141120
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:911201
[St] Status:MEDLINE


  7 / 93 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
[PMID]:1285399
[Au] Autor:Senior J; Marshall K; Sangha R; Baxter GS; Clayton JK
[Ad] Endereço:Postgraduate Studies in Pharmacology, University of Bradford.
[Ti] Título:In vitro characterization of prostanoid EP-receptors in the non-pregnant human myometrium.
[So] Source:Br J Pharmacol;102(3):747-53, 1991 Mar.
[Is] ISSN:0007-1188
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:1. Prostaglandin receptors of the PGE type have been characterized in the non-pregnant human myometrium in vitro according to the scheme of Coleman et al. (1984) by use of the agonists PGE2, sulprostone, rioprostil, AY23626, butaprost, misoprostol, 16,16-dimethylprostaglandin E2, enprostil and iloprost, and, the antagonist AH6809. 2. All prostanoids tested were active in non-pregnant human myometrium either as stimulators and/or inhibitors of spontaneous activity or both. Biphasic responses to PGE2 indicate that at least two receptor types of the EP-receptor exist, one mediating relaxation and the other mediating contraction. 3. Further evidence for the EP-receptor mediating excitation and relaxation was provided by the action of the EP2-/EP3-receptor selective prostanoids rioprostil, AY23626 and misoprostol, and the EP1-/EP2-receptor selective agonist 16,16-dimethylprostaglandin E2. 4. Butaprost, an EP2-receptor selective agonist, produced potent inhibition of spontaneous activity in the tissue which was generally longer-lasting than that evoked by the natural prostanoid PGE2. 5. The EP1-/EP3-receptor selective agonist sulprostone and the EP3-receptor agonist enprostil produced potent contractile responses supporting the presence of contractile EP3-receptors in the non-pregnant human myometrium in vitro. 6. The EP1-/IP-receptor selective agonist, iloprost, produced mixed responses in non-pregnant human myometrium. The contractile response was inhibited by the EP1-receptor antagonist AH6809. However, responses to the EP1-/EP3-receptor selective agonist sulprostone were unaffected by AH6809 which may indicate that only a small population of EP1-receptors is present. 7. Therefore it would seem that a heterogeneous population of EP-receptors is present in the non-pregnant human myometrium.
[Mh] Termos MeSH primário: Miométrio/efeitos dos fármacos
Receptores de Prostaglandina E/efeitos dos fármacos
Xantonas
[Mh] Termos MeSH secundário: Dinoprostona/farmacologia
Relação Dose-Resposta a Droga
Feminino
Seres Humanos
Iloprosta/farmacologia
Técnicas In Vitro
Misoprostol/farmacologia
Miométrio/fisiologia
Receptores de Prostaglandina E/análise
Rioprostila/farmacologia
Xantenos/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Receptors, Prostaglandin E); 0 (Xanthenes); 0 (Xanthones); 0E43V0BB57 (Misoprostol); 33458-93-4 (6-isopropoxy-9-oxoxanthene-2-carboxylic acid); 7JL402PVQR (Rioprostil); JED5K35YGL (Iloprost); K7Q1JQR04M (Dinoprostone)
[Em] Mês de entrada:9501
[Cu] Atualização por classe:141120
[Lr] Data última revisão:
141120
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:910301
[St] Status:MEDLINE


  8 / 93 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:2104796
[Au] Autor:Segers O; Somers G
[Ad] Endereço:Department of Internal Medicine, University Hospital AZ-VUB, Brussels, Belgium.
[Ti] Título:Effect of rioprostil, a methylprostaglandin E1 analog, on basal and stimulated plasma pancreatic hormone levels in man.
[So] Source:Dig Dis Sci;35(1):20-6, 1990 Jan.
[Is] ISSN:0163-2116
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The effect of rioprostil, a methylprostaglandin E1 analog on circulating pancreatic hormones was evaluated in 13 healthy male subjects. Rioprostil administration, 300 micrograms twice daily resulted in a significant decrease of fasting insulin, C-peptide, glucagon, and pancreatic polypeptide. No change in fasting plasma glucose or somatostatin levels was observed. An oral glucose tolerance test induced similar increments in plasma glucose concentration before and during treatment, but a delayed rise of insulin and C-peptide levels occurred during the administration of the drug. On rioprostil, the glucose load no longer inhibited peripheral glucagon or somatostatin. Treatment with rioprostil remained without effect on mixed meal-induced changes in plasma glucose levels and concomitant increases in insulin, pancreatic polypeptide, and somatostatin levels. It is concluded that in healthy individuals rioprostil influences the basal and glucose-induced levels of glucagon, insulin, and somatostatin. In healthy men this effect did not, however, result in glucose intolerance.
[Mh] Termos MeSH primário: Ilhotas Pancreáticas/efeitos dos fármacos
Hormônios Pancreáticos/sangue
Prostaglandinas E/farmacologia
Prostaglandinas Sintéticas/farmacologia
[Mh] Termos MeSH secundário: Adulto
Antiulcerosos/farmacologia
Glicemia/análise
Teste de Tolerância a Glucose
Seres Humanos
Masculino
Rioprostila
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Ulcer Agents); 0 (Blood Glucose); 0 (Pancreatic Hormones); 0 (Prostaglandins E); 0 (Prostaglandins, Synthetic); 7JL402PVQR (Rioprostil)
[Em] Mês de entrada:9002
[Cu] Atualização por classe:170822
[Lr] Data última revisão:
170822
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:900101
[St] Status:MEDLINE


  9 / 93 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:1975139
[Au] Autor:Metz-Kurschel U; Wagner K; Mueller MK
[Ad] Endereço:Department of Renal and Hypertensive Diseases, University Medical School, Essen, FRG.
[Ti] Título:The synthetic prostaglandin E1 analogue rioprostil reduces the nephrotoxic potential of cyclosporine A.
[So] Source:Transplant Proc;22(4):1713-6, 1990 Aug.
[Is] ISSN:0041-1345
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Acute CyA nephrotoxicity involves alteration in the proximal tubule and leads to glomerular lesions. Administration of a vasodilatator agent such as the prostaglandin E1 analogue Rioprostil (Bayer AG, BAY 06893) might prevent preglomerular vasoconstriction and hence reduce cyclosporin nephrotoxicity. As an increased excretion of urinary enzymes as a consequence of CyA-nephrotoxicity is well known we investigated in 40 male Wistar rats the excretion of three urinary enzymes: the brush border enzyme gamma-glutamyltransferase (GGT), the leucine aminopeptidase (LAP), and the lysosomal enzyme N-acetyl-beta-glucosaminidase (NAG). Additionally we determined s-creatinine and CyA plasma level. The kidneys were studied histologically at the end of the study. Wistar rats receiving 20 or 50 mg CyA/kg/d showed a marked deterioration in renal function and an increase of all urinary enzymes determined. In the rats receiving 20 mg CyA/kg/d and Rioprostil (150 micrograms/d) renal function and the enzymes determined remained in the normal range. There was no change in the enzyme excretion and only a minor improvement of renal function in rats receiving 50 mg CyA/kg/d and Rioprostil. Histological findings showed prevention of CyA nephrotoxicity in the 20 mg/kg/d group and diminished renal damage in the 50 mg/kg/d group.
[Mh] Termos MeSH primário: Ciclosporinas/toxicidade
Rim/patologia
Prostaglandinas E/farmacologia
Prostaglandinas Sintéticas/farmacologia
[Mh] Termos MeSH secundário: Acetilglucosaminidase/metabolismo
Animais
Creatinina/sangue
Ciclosporinas/sangue
Rim/efeitos dos fármacos
Rim/fisiologia
Leucil Aminopeptidase/metabolismo
Masculino
Microvilosidades/efeitos dos fármacos
Microvilosidades/enzimologia
Microvilosidades/ultraestrutura
Ratos
Ratos Endogâmicos
Valores de Referência
Rioprostila
gama-Glutamiltransferase/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cyclosporins); 0 (Prostaglandins E); 0 (Prostaglandins, Synthetic); 7JL402PVQR (Rioprostil); AYI8EX34EU (Creatinine); EC 2.3.2.2 (gamma-Glutamyltransferase); EC 3.2.1.52 (Acetylglucosaminidase); EC 3.4.11.1 (Leucyl Aminopeptidase)
[Em] Mês de entrada:9009
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:900801
[St] Status:MEDLINE


  10 / 93 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:2573147
[Au] Autor:Koop H; Schwarting H; Eckel U; Wagenknecht J; Hallfeldt U; Arnold R
[Ad] Endereço:Department of Medicine, Philipps University, Marburg, FRG.
[Ti] Título:Influence of chronic rioprostil treatment on gastric endocrine function.
[So] Source:Scand J Gastroenterol Suppl;164:104-10; discussion 110-1, 1989.
[Is] ISSN:0085-5928
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The influence of 4 weeks of treatment with the prostaglandin E1 analogue, rioprostil, 300 micrograms b.i.d., or placebo, on gastric endocrine function is tested in healthy male volunteers. Basal serum gastrin levels and postprandial gastrin output are unchanged after treatment with rioprostil. Similarly, plasma pancreatic polypeptide levels are unaffected. Antral gastrin tissue concentrations as well as antral somatostatin concentration and volume densities of antral G-cells and D-cells are unchanged. Neither basal nor pentagastrin-stimulated gastric acid secretion after rioprostil therapy differ from pretreatment values. Rioprostil, given in a dose of 100 micrograms b.i.d. to rats for 1 week significantly increases antral mucosal height but has no influence on the mucosal concentrations and cell densities of the gastric peptides, gastrin and somatostatin. It is concluded that rioprostil in the dose used does not affect the endocrine stomach after 4-weeks' administration at a dose of 300 micrograms b.i.d.
[Mh] Termos MeSH primário: Antiulcerosos/farmacologia
Glândulas Endócrinas/efeitos dos fármacos
Mucosa Gástrica/efeitos dos fármacos
Prostaglandinas E/farmacologia
[Mh] Termos MeSH secundário: Adulto
Animais
Método Duplo-Cego
Feminino
Gastrinas/metabolismo
Seres Humanos
Masculino
Polipeptídeo Pancreático/metabolismo
Prostaglandinas Sintéticas/farmacologia
Ratos
Ratos Endogâmicos
Rioprostila
Somatostatina/metabolismo
Fatores de Tempo
[Pt] Tipo de publicação:CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Anti-Ulcer Agents); 0 (Gastrins); 0 (Prostaglandins E); 0 (Prostaglandins, Synthetic); 51110-01-1 (Somatostatin); 59763-91-6 (Pancreatic Polypeptide); 7JL402PVQR (Rioprostil)
[Em] Mês de entrada:8912
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:890101
[St] Status:MEDLINE



página 1 de 10 ir para página                        
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde